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Enteric neurons from Parkinson’s 
disease patients display ex vivo 
aberrations in mitochondrial 
structure
A. S. Baumuratov1, P. M. A. Antony1,*, M. Ostaszewski1, F. He1,2, L. Salamanca1, L. Antunes3, 
J. Weber4, L. Longhino5, P. Derkinderen6, W. J. H. Koopman7,* & N. J. Diederich1,5,*
Based on autopsy material mitochondrial dysfunction has been proposed being part of the 
pathophysiological cascade of Parkinson’s disease (PD). However, in living patients, evidence for such 
dysfunction is scarce. As the disease presumably starts at the enteric level, we studied ganglionic and 
mitochondrial morphometrics of enteric neurons. We compared 65 ganglia from 11 PD patients without 
intestinal symptoms and 41 ganglia from 4 age-matched control subjects. We found that colon ganglia 
from PD patients had smaller volume, contained significantly more mitochondria per ganglion volume, 
and displayed a higher total mitochondrial mass relative to controls. This suggests involvement of 
mitochondrial dysfunction in PD at the enteric level. Moreover, in PD patients the mean mitochondrial 
volume declined in parallel with motor performance. Ganglionic shrinking was evident in the right but 
not in the left colon. In contrast, mitochondrial changes prevailed in the left colon suggesting that a 
compensatory increase in mitochondrial mass might counterbalance mitochondrial dysfunction in 
the left colon but not in the right colon. Reduction in ganglia volume and combined mitochondrial 
morphometrics had both predictive power to discriminate between PD patients and control subjects, 
suggesting that both parameters could be used for early discrimination between PD patients and 
healthy individuals.
Mitochondria are among the prime suppliers of energy (ATP) in virtually all living cells1,2 and empirical evidence 
suggests that their dysfunction is involved in the pathomechanism of Parkinson’s disease (PD)3–5. Despite con-
siderable progress, the potential role of mitochondrial (dys)function during PD development remains poorly 
understood. One of the main reasons for this lack of insight is the fact that there is no direct in vivo access to 
nigrostriatal dopaminergic neurons, the loss of which is one of the main pathological features of PD6. The lat-
ter study hypothesized the gastrointestinal tract may be the starting point of the disease and thus enteric neu-
rons may reliably reflect fundamental disease characteristics. Indeed, both Lewy neurites and Lewy bodies (LB), 
abnormal protein aggregates that develop in nerve cells during PD, have been demonstrated in the submucosal 
colon nerve layer of patients with early PD7–11. This suggests that pathological aberrations observed in enteric 
neurons might represent an early stage of PD manifestation7,8. Furthermore, animal studies of enteric neurons 
suggest a direct involvement of mitochondrial dysfunction in PD. It was suggested that inhibitory enteric neu-
rons are particularly vulnerable to mitochondrial dysfunction induced by Parkinsonian neurotoxins12. In this 
sense, mice treated with a chemical inhibitor of the first mitochondrial oxidative phosphorylation (OXPHOS) 
complex (complex I), displayed delayed gastric emptying in a dosage-dependent manner12,13. Similarly, severe 
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Figure 1. Workflow and image analysis procedure: The summarized workflow from colonoscopy to the analysis 
of 3D mitochondrial morphology is shown in (A). Schematic location of the submucosa layer and colon 
biopsy processing steps (B). Stretched biopsy represented as mosaic composed of 77 stitched images from the 
neurofilament channel (C). The arrows point to individual ganglia. Scale bar = 500 μ m. Image analysis steps (D): 
Mitochondrial volumes were defined via computational image analysis (D1abc). Ganglion masks were defined 
via manual surface selection from the neurofilament channel (D2ab) and transformed to volume information 
(D2c). All mitochondria not in contact with ganglia were removed (D3). Morphological analysis on segmented 
mitochondrial volumes was based on the distinction between mitochondrial surface and body (D3b) and on the 
analysis of mitochondrial branching (D3c). Branching analysis was based on the count of mitochondrial nodes. 
In the example highlighted in red, not only the circled branchpoint but also the mitochondrial endpoints labeled 1, 
2, and 3 are counted as nodes. Node degrees, as defined by the adjacency matrix proposed by Kerschnitzki et al.24,  
do not only count branches connected to a node (3 in this example), but the cumulated count of skeleton pixels 
in these branches. Scale bars for D1abc, D2abc, D3: 20 μ m. Scale bars for D3abc: 0,5 μ m.
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gastrointestinal dysmotility associated with degeneration of enteric neuronal and glial cells was demonstrated 
in a transgenic mouse model displaying impaired mitochondrial metabolism in these cells14. Accumulating evi-
dence suggests that cell metabolism and mitochondrial (dys)function are linked to mitochondrial (ultra)structure 
and motility1,15–18. Changes in mitochondrial morphology have been demonstrated in fibroblasts of PD patients 
with LRRK2 or Parkin mutations19,20. This suggests that mitochondrial morphology changes might be similarly 
indicative of the ongoing disease process in idiopathic PD. Here we investigated this hypothesis by quantitatively 
comparing 3D mitochondrial morphology and ganglion volume between colon biopsies from PD patients with-
out clinically apparent gastrointestinal dysfunction and age-matched control subjects. We developed an image 
quantification procedure allowing unbiased 3D analysis of mitochondrial morphology and ganglion volume in 
immunofluorescence images obtained by confocal microscopy. This revealed that ganglion volume and mito-
chondrial morphology were aberrant in PD patients and that these changes allowed discrimination between PD 
patients and healthy individuals.
Figure 2. Morphometric and clinical features used in this work. 
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Figure 3. Mitochondria and ganglia morphometrics of enteric neurons from patients and controls.  
(A) Mitochondria count per volume of patients and controls (p = 0.043). (B) Mitochondria count per volume 
between left and right colon location independently of disease status (p = 0.11). (C) Mitochondria count 
per volume compared between left and right colon location from patients only (p = 0.61). (D) Mitochondria 
count per volume compared between left and right colon location from controls only (p = 0.022). (E) Mean 
mitochondria volume of patients and controls (p = 0.197). (F) Normalized mitochondrial mass of patients and 
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Results
The enrolled subjects were of similar age (PD patients: 70 ± 6 years; controls: 65 ± 5 years; P = 0.17). There 
were five male and six female patients and one male and three female controls. In patients the average disease 
duration at the time of colon biopsy was 5.4 ± 5.7 years. The average Unified Parkinson’s Disease Rating Scale 
(UPDRS) motor score describing disease progression equaled 10.7 ± 8.1. The mean levodopa equivalent dosage 
was 630.3 ± 483 mg21. Following random selection of the biopsies, we analyzed 65 biopsies from PD patients and 
41 biopsies from healthy subjects in detail.
Image analysis algorithm and parameters. The biopsies were processed as illustrated in Fig. 1. For auto-
mated segmentation of mitochondria within a ganglion, deconvolved Alexa-488 channel images were adjusted 
to 16 bit by multiplying each pixel value with the ratio between the theoretical maximum of a 16 bit pixel, namely 
216 − 1, and the maximum pixel value of the 12 bit image to be adjusted. Mitochondrial pixels were defined using 
two rules: first, local thresholds had to confirm that local signals obtained from a 5 pixel sized Gaussian filter with 
a standard deviation of 2 were at least 25% brighter than the surrounding background, as defined by a 10 × 10 
average filter. Second, foreground signals in non-uniformly corrected image stacks had to be confirmed via global 
thresholds according to the Otsu method, in which an optimal threshold is selected by maximizing the measure of 
separability between foreground and background in terms of gray levels22. Correction of non-uniform illumina-
tion was performed by subtracting 20 × 20 average filtered images from the corresponding deconvolved images. 
To remove shot noise, which occurs in photon counting devices, connected components fulfilling both mito-
chondrial pixel recognition criteria were filtered for a volume of at least eight pixels23. Objects with more than 
106 pixels were removed from the mitochondria mask. Mitochondrial feature extraction was restricted to con-
nected components intersecting with the ganglion volume. For segmentation of mitochondrial surface and mito-
chondrial body, the mitochondrial mask was eroded with a structuring element defined by a center pixel and its 
6-connected neighbourhood. Skeletonization of the mitochondrial 3D mask was performed as described before24. 
Figure 1 and the Supp. Movie 1 shows the resulting mitochondrial volumes, surfaces, eroded bodies, and skeletons in 
3D. In addition, we show the mitochondrial state in both healthy controls and PD patients (Supplementary Figure 1). 
Overall, 7 features describing mitochondrial morphology in a ganglion were analyzed Fig. 2.
Mitochondrial morphometrics. 3D immunofluorescence image stacks were acquired by confocal micros-
copy from fixed colon biopsies, as described above. These stacks were used to first reconstruct and subsequently 
quantify 3D ganglion and mitochondrial structural features. The number of mitochondrial objects per ganglion, 
corrected for ganglion volume (Fig. 2; MitoCount), was higher in PD patients than in control subjects (Fig. 3A; 
P = 0.043). In the whole cohort (including PD patients and controls), there was no difference in MitoCount 
between the right and left colon (Fig. 3B; P = 0.11). Also in PD patients MitoCount was not significantly different 
between the right and left colon (Fig. 3C; P = 0.61). In control individuals, in contrast, MitoCount was higher in 
the right colon than in the left colon (Fig. 3D; P = 0.022). Total mitochondrial volume normalized to ganglion 
volume (Fig. 2; MitoVolumeTotal) is a measure of mitochondrial mass25. In the pooled colon samples from right 
and left colon MitoVolumeTotal was higher in PD patients than controls (Fig. 3F; P = 0.017).
While there was no difference in mean mitochondrial volume (Fig. 2; MitoVolumeMean) between PD patients 
and controls (Fig. 3E; P = 0.197), these volumes showed a significant gradient from left to right colon in PD 
patients, but not in controls (Fig. 3G; P = 0.028 and Fig. 3H; P = 0.076). Taken together, PD patients displayed a 
lower MitoVolumeMean in the right colon than in the left colon, whereas controls did not.
We compared the mitochondrial features with the clinical parameters of PD patients. This revealed that 
decreasing mean mitochondrial volume was linked to an increasing UPDRS motor score, which reflects reduced 
motor performances (Fig. 4; P = 0.04; rho = − 0.258, Spearman ranked test). Importanly, none of the features was 
linked to the age of the participants.
Ganglion morphometrics. Average ganglion volume (Fig. 2; GanglionVolume) was significantly smaller in 
PD patients (17233 ± 14627 μ m3) than in controls (27384 ± 22255 μ m3) (Fig. 3I; P = 0.005). Comparing the right 
(n = 50) and the left colon (n = 56) of the whole cohort (including PD patients and controls), revealed that the 
GanglionVolume was larger in the right than in the left colon (Fig. 3J; P = 0.004). However, the GanglionVolume 
for the right colon was smaller in PD patients than in controls (Fig. 3K; P = 0.0006). A significant gradient in 
GanglionVolume along the colonic tract was observed in controls but not in patients (Fig. 3N,M). ROC curve 
analysis using the right-colon GanglionVolume revealed a high AUC value of 0.81, indicating that this feature 
displays high specificity and sensitivity in discriminating between PD patients and controls (Fig. 3L).
controls (p = 0.017). (G) Mean mitochondria volume comparison between left and right colon location from 
patients only (p = 0.028). (H) Mean mitochondria volume comparison between left and right colon location 
from controls only (p = 0.076). (I) Ganglia volume of patients and controls (p = 0.005). (J) Ganglia volume 
comparison between left and right colon location independently of disease status (p = 0.004). (K) Ganglia 
volumes from the right colon of patients and controls (p = 0.0006). (L) ROC analysis. The corresponding 
p-value 2.3e-4 indicates the random chance that the AUC is not different from 0.5 (null hypothesis: AUC = 0.5). 
(M) Ganglion volumes of patients compared between left and right colon (p = 0.33). (N) Ganglion volumes of 
controls compared between left and right colon (p = 0.002). All features are plotted on log scales (A–K,M,N). 
AUC = area under the curve; PD = Parkinson’s disease; ROC = receiver operating curve.
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Results extended by principal component analysis and support vector machine learning. 
Feature-by-feature comparison for the pooled ganglion data revealed that five morphometric features differed 
between PD patients and controls (Fig. 5A). Also five features differed between PD patients and controls in the 
left colon (Fig. 5B). In contrast, a single feature differed between PD patients and controls in the right colon 
(Fig. 5C). Next, we performed a principal component analysis (PCA), that simultaneously considers all variables 
in a multidimensional space26–28. In the context of data visualization, PCA is widely used to reduce data dimen-
sionality while retaining most of the variance of the data, thereby allowing graphic visualization26. It accomplishes 
this reduction by identifying directions, called Principal Components (PCs), along which the variance of the data 
is maximal. PCA revealed that a single outlier was present in the dataset (Fig. 6A; green circle). This information 
was used for the training of the SVM classifier, where parameters were set to assume 1% of outliers. Separate SVM 
analysis of the overall mitochondrial morphological phenotype in the right (AUC = 0.74) and in the left colon 
(AUC = 0.71), using the seven mitochondrial features, indicates that mitochondrial morphometrics provide use-
ful information for the discrimination between PD patients and healthy control subjects (Fig. 6B–D).
Integrating mitochondrial and ganglion morphometrics. Integrating mitochondrial and ganglion 
morphometric information might leverage the classification of PD patients and control subjects. To test this 
hypothesis we determined whether such an integration increases classification accurary. Right colon samples 
from patients displayed reduced ganglion volume (Fig. 5C) and an AUC-value with respect to mitochondrial 
morphometrics of 0.74 (Fig. 6B). When ganglion volume information was combined with information from 
mitochondrial morphometrics, two thresholds were required for classifying ganglia from PD patients or healthy 
subjects: one for the SVM score representing the predictive information from mitochondrial morphometrics, and 
one for ganglia volumes. These thresholds were set using the prior knowledge that 40% of the analyzed ganglia 
were derived from healthy controls and 60% from PD patients (Fig. 6E). The predictive power of a classifier com-
bining both sets of information reached a sensitivity (true positive rate) of 0.63 and a specificity (1 - false positive 
rate) of 0.9 (Fig. 6E). This means that this classifier, independently from clinical diagnosis, could identify 63% of 
patients in this study as true positives. Importantly, 90% of the predicted patients would be correctly diagnosed 
by this combinatorial classifier while the remaining 10% would be false positives. At the same rate of 10% false 
positives, the sensitivity for ganglion volume based classification (Fig. 3L) and mitochondria based classification 
(Fig. 6D) was below 0.63 in the right colon. This reveals that combination of morphometric features from ganglia 
and mitochondria increases the classification accuracy of PD patients and healthy subjects.
Figure 4. Analysis of correlation between clinical patient data, mitochondrial features, and ganglia 
volumes. Mitochondrial features are described in Fig. 2. GV, Ganglion volume; SumMMSE, Score from 
Mini-Mental State Examination; UPDRSIII, Motor part of the Unified Parkinson’s Disease Rating Scale; 
SchwabEngland, Score for individual levels of independence. Spearman’s rank correlation coefficients are 
color coded as indicated in the colorbar. Grouping of similar rows and columns in the matrix of coefficients, as 
illustrated by dendrograms, was done via hierarchical clustering with Euclidean distance metric and average 
linkage in Matlab.
www.nature.com/scientificreports/
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Discussion
Accumulating evidence suggests that aberrations in enteric neurons might be an early feature of PD29–31. To 
address this hypothesis we compared mitochondrial morphology between ex vivo enteric ganglia from PD 
patients (11 patients, 65 ganglia) and healthy age-matched control subjects (4 subjects, 41 ganglia).
Morphometrics in 3D reveal mitochondrial changes in the enteric nervous system. Microdissection 
of colonic submucosa, introduced by Lebouvier et al.9,32 leveraged the immunofluorescence based study of gan-
glia. Here, we developed an image analysis algorithm for the quantification of mitochondrial morphometrics 
within ganglia volumes. To maximize spatial information retrieval and establish unbiased and reproducible mor-
phometric measurements, the whole 3D image data set was analysed33,34.
Our data confirms that progressive mitochondrial fragmentation occurs in parallel with progressing motor 
deficits. An even more robust correlation with clinical findings may be foreseen in larger cohorts, with recruit-
ment of patients in late stages of the disease, and with directly PD-linked gastrointestinal symptoms. The observed 
reduced ganglion volumes in PD patients are in line with the idea of enteric neurodegeneration as an early patho-
genic event. Mitochondrial fragmentation, increased number of mitochondria, and increased total mitochondrial 
mass suggest a functional connection between mitochondrial morphofunction and ganglion degeneration.
Rostrocaudal gradient of ganglion morphometrics in PD patients. The observed changes differed 
between the right and left colon of PD patients. Although PD patients did not display clinically apparent gastro-
intestinal dysfunction, their right colon ganglia had a reduced volume. Importantly, this right colon ganglion 
degeneration had predictive power to discriminate between PD patients and control subjects. The selective gan-
glion volume reduction in the right colon is in line with the previously proposed rostrocaudal gradient of enteric 
neuropathology along the digestive tube of PD patients35,36, characterized by a more pronounced pathology in 
proximal parts of the gastrointestinal tract, such as esophagus, than in distal parts of the gastrointestinal tract, 
such as the colon. We observed in this study that even within the colon such a gradient can be shown. Both 
healthy individuals and patients displayed a lower mean mitochondrial volume in the right colon relative to the 
left colon. This difference was significant for patients and borderline significant in the control group. To elucidate 
if mitochondrial changes are predominant in the right or left colon, each colon region was directly compared 
between patients and controls, as discussed in the next section.
Lack of neuroprotective mitochondrial compensation in the right colon. Statistical comparison 
of single mitochondrial features between patients and healthy subjects only revealed significant differences in the 
Figure 5. Ganglion and mitochondrial morphometric features. Comparision of pooled ganglion data from 
left and right colon between patients and controls (A). Comparison of left colon ganglia between patients and 
controls (B). Comparison of right colon ganglia between patients and controls (C). All features are plotted on 
log scale axes and described in Fig. 2.
www.nature.com/scientificreports/
8Scientific RepoRts | 6:33117 | DOI: 10.1038/srep33117
Figure 6. Evaluation of disease status classification. Principle component analysis of mitochondrial 
features in the whole study cohort (A). Each data point represents a single ganglion. Shapes and color codes 
indicate disease state and colonic sample location as shown in the legend. Evaluation of ganglion classification 
via mitochondrial morphometrics and support vector machines (B–D); AUC analysis was based on one 
hundred five-fold cross validations via support vector machine classification on patient or control ganglia. The 
combination of underlying mitochondrial scores and ganglion volumes in the right colon is used with the prior 
information that 60% of samples in this study are derived from patients and 40% from controls. Setting the 
MitoSVM score threshold to the quantile 0.6 of MitoSVM scores and the threshold for GangliaVolume - larger 
in patients than in controls - to the quantile 0.4 of GangliaVolumes provides a biomarker based classifier with a 
sensitivity of 0.63 and a specificity of 0.9 (E).
www.nature.com/scientificreports/
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left colon. Mitochondrial changes in the right colon could only be demonstrated using machine learning tech-
niques that combined multiple features. This might suggest that significant mitochondrial structural changes in 
the right colon are absent or have already occurred at an earlier timepoint. Mitochondrial fragmentation has been 
proposed as one of the earliest subcellular markers of neurodegeneration37. This is in line with the observed mito-
chondrial fragmentation in the present cohort composed of PD patients at a rather early disease stage. However, 
the findings should be confirmed in PD patients at a yet earlier motor stage or in subjects with REM sleep behav-
ior syndrome, an established forerunner syndrome of PD38. The increase in total mitochondrial mass in the 
left colon of PD patients might reflect a compensatory mechanism to sustain mitochondrial functioning39,40. 
Alternatively, increased mitochondrial mass might be due to impaired mitophagy41,42.The normal ganglion vol-
umes observed in the left colon of PD patients support the idea of successful mitochondrial adaptation. Indeed, 
in fibroblasts derived from patients with Parkin mutation, paraquat exposure increased the mitochondrial mass 
but directly reduced mitochondrial branching and ATP production43.
The finding of intact ganglia in the left colon and shrunken ganglia in the right colon suggests a two-stage pro-
cess: at first mitochondrial changes are efficiently compensatory and neuroprotective, but they are inexorably fol-
lowed by the breakdown of cellular homeostasis further triggering cellular apoptosis and ganglia shrinking. Such 
a pathophysiological cascade is in line with the presented rostrocaudal gradient in mitochondrial fragmentation 
in PD. The rostrocaudal gradient theory is also supported by the fact that microbiota composition varies along the 
digestive tract44. A radial gradient in oxygene pressure from the intestinal tissue interface to the intestinal lumen 
indicates oxygene diffusion from host to microbiota45, which might interfere with oxidative phosphorylation in 
the enteric submucosa. Indeed, it is recognized that the brain-gut axis including central, autonomic, and enteric 
nervous systems is significantly modulated by gut microbiota46.
Potential links between morphometric changes, alpha-synuclein, and pathogenesis. In com-
plement to morphological changes in ganglion mitochondria, reported in the present study, prior studies reported 
abnormal protein aggregates in the colonic neurons of early-stage PD patients7–11. It has been proposed that mis-
folded alpha-synuclein directly alters mitochondria and their associated membranes47,48. In this perspective, the 
observed mitochondrial morphology changes are also in line with established neuropathological involvement of 
the enteric nervous system in PD29–31.
Due to lack of material, we did not evaluate the role of LB burden, so far considered to be primordial7–9. 
Although not uncontested, it had been proposed that ganglionic cell degeneration may be secondary to LB bur-
den. Esophageal LB were first identified in PD patients with dysphagia49. Later LB were found in ganglia cells 
from the colonic myenteric plexus in a PD patient suffering from megacolon29. The presence of LB in other parts 
of the gastrointestinal tract was confirmed by others ever since30,32. Clinically asymptomatic patients with Braak 
stage 2 brain pathology also show LB pathology in ganglia located in the intramural and submucosa layers50. 
However, none of these studies analyzed mitochondrial alterations51,52. To the best of our knowledge, the present 
study is the first ex vivo study exploring mitochondrial morphometrics in the colon of PD patients.
The methodological approach is innovative for the field, but, importantly, requires deeper biopsy samples than 
usually collected. The thereby increased risk for injury and the true positive rate of only 63% vetoes the use of this 
method for large scale diagnostic screening. However, as colonoscopy is, at least in some countries, systematically 
used for colon cancer screening, and as the methods that we present here provide low false positive rates, 3D gan-
glion and mitochondria morphometrics offer new opportunities for the early validation of preliminary PD diag-
nosis. Furthermore, the presented approach could leverage the study of mitochondrial morphometrics in other 
neurodegenerative diseases such as Alzheimers’s disease, and Huntington’s disease, which have also been linked 
to mitochondrial dysfunction53. While mitochondrial sizes are at the resolution limit of conventional microscopy, 
our sophisticated method using advanced confocal microscopy, deconvolution, and computational image anal-
ysis, successfully manages this barrier and yields reproducible quantification of mitochondrial morphometrics 
within the ganglia. However, confirmation in larger cohorts and by another imaging approach such as electron 
microscopy or indirect proof by metabolic studies are essential.
We are aware of the caveats and restrictions of such a pioneer study. Mitochondrial morphometrics give only 
a snapshot view on the complex and rapidly ongoing process of mitochondrial dynamics. Within ganglia the view 
is limited to the direct surroundings of the nucleus and does not extend beyond the ganglia limits, to distal parts 
of the axons, and most importantly to the synaptic level54. Furthermore, the enteric neurons at the submucosal 
level essentially modulate mucosal processes, while those at the myenteric level control the motor activity, i.e., are 
responsible for dysmotility syndromes including constipation as seen in PD55. Separate analysis of the different 
enteric neuron subpopulations, such as inhibitory motor neurons, ascending interneurons and excitatory longi-
tudinal muscle motor neurons may further enhance the discriminative power56. Future studies should include 
patients with overt dysmotility syndrome and patients at later motor stages of disease.
Conclusion
Studying mitochondrial morphology in enteric neurons of PD patients is appealing as there are numerous simi-
larities between enteric neurons and striatal dopaminergic neurons: high complexity and branching, low level of 
myelination, and long axon size. In both cell types mitochondria have to travel a long distance from the cell body 
to the dendritic or synaptic processes. Mitochondrial dynamics have to be performant, both in terms of adequate 
organelle fusion/fission and transport to distant cellular locations. High adaptability mediating robustness against 
mitochondrial stress has thus to be presumed, already in the healthy condition. With this analogy between enteric 
and striatal neurons in mind, our study is the first ex vivo proof in humans on mitochondrial dysfunction in 
Parkinson’s disease by detecting altered mitochondrial morphometrics in the colon.
www.nature.com/scientificreports/
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Methods
Recruitment procedure, tissue preparation, staining and fluorescence microscopy. 
Colonoscopy in Luxemburg is offered within a colon cancer-screening program to individuals between the age 
of 50 and 80. Here this procedure was carried out with consecutive, non-demented patients with idiopathic PD, 
according to the London Brain Bank criteria57. These PD patients displayed no clinically apparent gastrointestinal 
symptoms and their age was within the above range. Healthy, age-matched volunteers were recruited as controls. 
All participants had given informed written consent prior to participating in this study. The study, the detailed 
experimental protocols as well as the information sheet for the patients were authorized and approved by the 
National Research Ethics Committee of Luxembourg (decision 201107/03), according to the rules established by 
the International Conference on Harmonisation (ICH) and the Declaration of Helsinki. All subjects underwent 
a standardized examination program as previously described58. All biopsies were taken by the same experienced 
gastroenterologist (W.J.). For each individual, at least one biopsy was obtained from the proximal/right colon tract 
and at least one biopsy was taken from the distal/left colon tract. Biopsies were stretched and pinned flat using 
needles (FST#26002-10, Minutien Pins, FST) using established protocols9,32, as illustrated (Fig. 1B). Submucosa 
was mechanically dissected from the mucosal tissue using a stereomicroscope and watchmaker’s forceps. The 
submucosa samples were fixed in 4% w/v paraformaldehyde for 2 h at room temperature. After three subsequent 
washing steps (10 min each), the specimen was permeabilized for 1.5 h in Dulbecco’s Phosphate Buffered Saline 
(D8537, SigmaAldrich, MO, USA ) containing 1% v/v Triton X-100 (T8787, SigmaAldrich, MO, USA) and 1% 
w/v bovine serum albumin (A2058, SigmaAldrich, MO, USA). After another short wash, it was incubated for 
45 minutes in a blocking solution (dPBS + 5% v/v goat serum, S-1000, Vector laboratories, Inc., CA, USA). We 
applied primary antibodies including anti-neurofilament-L (C-term) rabbit monoclonal antibody (Cat. #04-
1112, Millipore), and anti-mitochondria mouse monoclonal antibody (Cat. #MAB1273, Millipore). These were 
diluted in dPBS containing 1% v/v Triton X-100 + 1% w/v BSA and incubated for 12 hours at a temperature of 
4 °C. Following incubation with the primary antibodies, samples were washed three times with dPBS (10 min-
utes each) and then incubated for three hours at room temperature with secondary antibodies: Alexa-555 goat 
anti-rabbit (Cat. #A21428, Invitrogen) and Alexa-488 goat anti-mouse (Cat. #A11001, Invitrogen), diluted 1:500 
in dPBS. After three additional washing steps with dPBS, the submucosa was mounted on a microscope glass 
slide (Fluoroshield with DAPI, Sigma-Aldrich) and covered with a cover glass. Images were acquired with a 
confocal microscope (LSM 710, Zeiss, Germany). Each biopsy slide was visually inspected by the operator using 
a 20× air objective (Zeiss, Plan-Apochromat, NA = 0.8) to locate ganglia. After this step, the area containing 
ganglion material was scanned using an objective with a higher magnification (63× , oil, Zeiss, Plan-Apochromat, 
NA = 1.4), resulting in a 3D image stack. The pinhole was set to acquire 1.5 μ m sections. The size of z-steps was set 
to 0.18 μ m. DAPI was excited using the 405 nm laser line. Fluorescence between 410–483 nm was filtered using 
a 3-Channel Quasar Detection Unit and detected using a photomultiplier tube (PMT). Alexa-488 was excited 
using the 488 nm laser line and fluorescence was detected using a 500–550 bandpass filter and a gallium arsenide 
phosphide detector. Alexa-555 was excited with a 561 nm laser and fluorescence was detected using a 565–610 
bandpass filter and a gallium arsenide phosphide detector. All lightpaths passed a 488/561 main beam splitter. 
For DAPI, an additional 405 beamsplitter placed between 405 laser, main beam splitter, and sample was used. 
The gallium arsenide phosphide detectors were placed behind a 545 long pass filter while the light reflected from 
this filter was targeting the DAPI detector. All used filters, beamsplitters, and detection units are from Zeiss. The 
detection mode was set to photon counting. The size of acquired images was adjusted to ganglion size. Alexa-488 
fluorescence was acquired in a first scan. DAPI and Alexa-555 fluorescence were acquired simultaneously in a 
second scan.
Image analysis. 3D image stacks were imported into AutoQuant X (version X3.0.3 64-bit edition, Media 
Cybernetics, Rockville, MD, USA) and deconvolved using an adaptive point spread function (10 iterations). 
Deconvolved stacks were further processed in Imaris 8.1.2 (Bitplane, Switzerland). Iso-surfaces of ganglia were 
reconstructed by manually selecting regions of interest (ROIs), corresponding to the convex hull of cells con-
taining neurofilaments, for each individual slice. To export the ROI to Matlab 2014a (Mathworks, MA, USA), 
3D surfaces were converted to ganglion volume masks. The image analysis procedure for mitochondrial analysis 
in Matlab, as well as the underlying settings for image processing, are presented in detail in the Results section.
Statistical analysis. All investigators (except statisticians) were blinded for the identity of the barcoded 
samples. In total, a number of 89 anonymized biopsies (48 from the right colon and 41 from the left colon) were 
analyzed. In these biopsies 329 ganglia were identified (175 from the right and 154 from the left colon), 106 of 
which were randomly chosen for analysis using the default pseudorandom number generator provided by the R 
package, which uses the Mersenne-Twister algorithm. Whenever possible, at least two ganglia from the right and 
left colon were included for each subject. Significance of the differences between features were evaluated using a 
permutation test59: For comparing vectors of features, the true absolute mean difference was calculated. Then, the 
labels between compared vectors were randomly shuffled and the absolute mean difference was calculated. The 
random shuffling was repeated 100000 times. The P-value was calculated by comparing the true absolute mean 
with the absolute means from random shuffling. The classic approach to evaluate the diagnostic performance of 
a potential biomarker(s) is the receiver operating characteristic (ROC) analysis60,61, which plots the true-positive 
rate (sensitivity) against the false-positive rate (1-specificity) for a given biomarker or a combination of biomark-
ers. We applied a ROC analysis to determine whether mitochondrial and/or ganglial features could be used for 
discriminating between PD patients and healthy subjects. The area under the ROC curve (AUC) is a measure of 
the diagnostic performance (1 indicating a perfect diagnostic power while 0.5 indicates a futile biomarker). In 
addition to the above approaches, we used principal component analysis (PCA) for the data visualization, and lin-
ear support vector machines (SVM)62 for binary classification of PD patients and healthy subjects. To this end the 
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SVM model was first trained using the whole dataset. The predictions obtained were then validated by running 
100 experiments of 5-fold cross-validation using a linear SVM classifier. In this approach, each iteration uses 4/5 
of the dataset to train the SVM classifier that determines how to split between classes (i.e., PD patients and healthy 
subjects), and then evaluates the rates of true and false positives in the remaining dataset. This way we ensure the 
independence between the training and test set, essential to ensure the generalization of the approach. Both PCA 
and SVM analysis were done in Matlab.
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